<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Cancer Urology</journal-id><journal-title-group><journal-title xml:lang="en">Cancer Urology</journal-title><trans-title-group xml:lang="ru"><trans-title>Онкоурология</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1726-9776</issn><issn publication-format="electronic">1996-1812</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1950</article-id><article-id pub-id-type="doi">10.17650/1726-9776-2025-21-3-142-147</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>CLINICAL NOTES</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>КЛИНИЧЕСКИЕ СЛУЧАИ</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Multimodal treatment of oligometastatic cancer of ectopic intrathoracic kidney with Bochdalek’s hernia: сlinical observation and literature review</article-title><trans-title-group xml:lang="ru"><trans-title>Комплексное лечение олигометастатического рака дистопированной в грудную полость почки при грыже Бохдалека: клиническое наблюдение и обзор литературы</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Lakhno</surname><given-names>D. A.</given-names></name><name xml:lang="ru"><surname>Лахно</surname><given-names>Д. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>dmitry_lakhno@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0002-4361-817X</contrib-id><name-alternatives><name xml:lang="en"><surname>Semenova</surname><given-names>Y. M.</given-names></name><name xml:lang="ru"><surname>Семенова</surname><given-names>Ю. М.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>yuliyasemyon@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1322-9862</contrib-id><name-alternatives><name xml:lang="en"><surname>Zingerenko</surname><given-names>M. B.</given-names></name><name xml:lang="ru"><surname>Зингеренко</surname><given-names>М. Б.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>zingerenkom@mail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Meskikh</surname><given-names>A. V.</given-names></name><name xml:lang="ru"><surname>Меских</surname><given-names>А. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>meskih@mail.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5169-2199</contrib-id><name-alternatives><name xml:lang="en"><surname>Tsvirkun</surname><given-names>V. V.</given-names></name><name xml:lang="ru"><surname>Цвиркун</surname><given-names>В. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>v.tsvirkun@mknc.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">A.S. Loginov Moscow Clinical Research Center, Moscow Healthcare Department</institution></aff><aff><institution xml:lang="ru">ГБУЗ г. Москвы «Московский клинический научно-практический центр им. А. С. Логинова Департамента здравоохранения г. Москвы»</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Outpatient Oncology Care Center – branch of A. S. Loginov Moscow Clinical Research Center, Moscow Healthcare Department</institution></aff><aff><institution xml:lang="ru">Центр амбулаторной онкологической помощи – филиал ГБУЗ г. Москвы «Московский клинический научно-практический центр им. А. С. Логинова Департамента здравоохранения г. Москвы»</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2025-12-18" publication-format="electronic"><day>18</day><month>12</month><year>2025</year></pub-date><volume>21</volume><issue>3</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>142</fpage><lpage>147</lpage><history><date date-type="received" iso-8601-date="2025-06-06"><day>06</day><month>06</month><year>2025</year></date><date date-type="accepted" iso-8601-date="2025-07-24"><day>24</day><month>07</month><year>2025</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2025, Lakhno D.A., Semenova Y.M., Zingerenko M.B., Meskikh A.V., Tsvirkun V.V.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2025, Лахно Д.А., Семенова Ю.М., Зингеренко М.Б., Меских А.В., Цвиркун В.В.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="en">Lakhno D.A., Semenova Y.M., Zingerenko M.B., Meskikh A.V., Tsvirkun V.V.</copyright-holder><copyright-holder xml:lang="ru">Лахно Д.А., Семенова Ю.М., Зингеренко М.Б., Меских А.В., Цвиркун В.В.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://oncourology.eco-vector.com/oncur/article/view/1950">https://oncourology.eco-vector.com/oncur/article/view/1950</self-uri><abstract xml:lang="en"><p>In 2023 in Russia, 26,385 new cases of kidney cancer were registered. At diagnosis, per various estimations, up to 30 % of patients have distant metastases of renal cell carcinoma. Surgical treatment is considered the method of choice in patients with renal cell carcinoma with solitary (&lt;2) metastases of any location which can be resected simultaneously or sequentially with the primary tumor. Intrathoracic kidney is observed in less than 5 % of ectopic kidney cases. In literature, only individual cases of treatment of patients with diagnosed cancer of ectopic intrathoracic kidney with Bochdalek’s hernia are described.</p> <p>The article presents a clinical observation of treatment of a patient with oligometastatic cancer of ectopic intrathoracic left kidney: radical surgical treatment with simultaneous reconstruction of diaphragmatic hernia and subsequent adjuvant therapy with PD-1 (programmed cell death 1 receptor) inhibitor.</p></abstract><trans-abstract xml:lang="ru"><p>В России в 2023 г. было зарегистрировано 26 385 новых случаев рака почки. При постановке диагноза, по разным оценкам, до 30 % пациентов имеют отдаленные метастазы почечно-клеточного рака. Хирургическое лечение рассматривается как метод выбора у пациентов с почечно-клеточным раком с солитарными (&lt;2) метастазами любой локализации, которые могут быть радикально удалены одномоментно или последовательно с первичной опухолью. Интраторакальное расположение почки встречается менее чем в 5 % почечных эктопий. В литературе представлены единичные наблюдения лечения пациентов с диагностированным раком эктопированной в грудную полость почки при грыже Бохдалека.</p> <p>В статье представлено клиническое наблюдение лечения пациента с олигометастатическим раком дистопированной в грудную полость левой почки – радикальное хирургическое лечение с симультанной пластикой диафрагмальной грыжи и последующим проведением адъювантной терапии ингибитором PD-1 (programmed cell death 1, рецептор программируемой клеточной смерти лимфоцитов 1).</p></trans-abstract><kwd-group xml:lang="en"><kwd>renal cell carcinoma</kwd><kwd>Bochdalek’s hernia</kwd><kwd>oligometastatic</kwd><kwd>surgical treatment</kwd><kwd>adjuvant therapy</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>почечно-клеточный рак</kwd><kwd>грыжа Бохдалека</kwd><kwd>олигометастатический</kwd><kwd>хирургическое лечение</kwd><kwd>адъювантная терапия</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Cirillo L., Innocenti S., Becherucci F. Global epidemiology of kidney cancer. Nephrol Dial Transplant 2024;39(6):920–8. DOI: 10.1093/ndt/gfae036</mixed-citation></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">Malignant tumors in Russia in 2023 (morbidity and mortality). Eds.: А.D. Kaprin, V.V. Starinskiy, A.O. Shakhzadova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMITS radiologii” Minzdrava Rossii, 2024. 276 p. (In Russ.).</mixed-citation><mixed-citation xml:lang="ru">Злокачественные новообразования в России в 2023 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, О.В. Шахзадовой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2024. 276 с.</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><mixed-citation>Renner A., Samtani S., Marín A., Burotto M. Is cytoreductive nephrectomy still a standard of care in metastatic renal cell carcinoma? J Kidney Cancer VHL 2019;6(1):1–7. DOI: 10.15586/jkcvhl.2019.114</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Bianchi M., Sun M., Jeldres C. et al. Distribution of metastatic sites in renal cell carcinoma: a population-based analysis. Annal Oncol 2012; 23(4):973–80. DOI: 10.1093/annonc/mdr362</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Schumpelick V., Steinau G., Schlüper I. et al. Surgical embryology and anatomy of the diaphragm with surgical applications. Surg Clin North Am 2020;80(1):213–39. DOI: 10.1016/S0039-6109(05)70403-5</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Ramspott J.P., Jäger T., Lechner M. et al. A systematic review on diagnostics and surgical treatment of adult right-sided Bochdalek hernias and presentation of the current management pathway. Hernia 2022;26(1):47–59. DOI: 10.1007/s10029-021-02445-1</mixed-citation></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">Plaksin S., Kotelnikova L. Diagnostics and surgical tactics for Bogdalek hernias in adults. Khirurgiya = Surgery 2023;(6):48–55. (In Russ.). DOI: 10.17116/hirurgia202306148</mixed-citation><mixed-citation xml:lang="ru">Плаксин С.А., Котельникова Л.П. Диагностика и хирургическая тактика при грыжах Богдалека у взрослых. Хирургия 2023;(6):48–55. DOI: 10.17116/hirurgia202306148</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><mixed-citation>Fiaschetti V., Velari L., Gaspari E. et al. Adult intra-thoracic kidney: a case report of Bochdalek hernia. Case Rep Med 2010:1–6. DOI: 10.1155/2010/975168</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Sharma P., Keenan R.J., Sexton W.J. Mass in solitary intrathoracic kidney within Bochdalek hernia. Urology 2016;97:e15–6. DOI: 10.1016/j.urology.2016.08.017</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Méjean A., Ravaud A., Thezenas S. et al. Sunitinib alone or after nephrectomy for patients with metastatic renal cell carcinoma: is there still a role for cytoreductive nephrectomy? Eur Urol 2021;80(4):417–24. DOI: 10.1016/j.eururo.2021.06.009</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Motzer R.J., Jonasch E., Michaelson M.D. et al. NCCN guidelines insights: kidney cancer, version 2.2020. J Natl Compr Canc Netw 2019;17(11):1278–85. DOI: 10.6004/jnccn.2019.0054</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Ouzaid I., Capitanio U., Staehler M. et al. Young Academic Urologists Kidney Cancer Working Group of the European Association of Urology. Surgical metastasectomy in renal cell carcinoma: a systematic review. Eur Urol Oncol 2019;2(2):141–9. DOI: 10.1016/j.euo.2018.08.028</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Suzuki K., Hara T., Terakawa T. et al. The efficacy of surgical metastasectomy for solitary metastasis of renal cell carcinoma. Urol Int 2022;106(4):397–403. DOI: 10.1159/000516679</mixed-citation></ref><ref id="B14"><label>14.</label><citation-alternatives><mixed-citation xml:lang="en">Renal parenchyma cancer. Clinical guidelines of the Russian Ministry of Health. Available at: https://cr.minzdrav.gov.ru/view-cr/10_4</mixed-citation><mixed-citation xml:lang="ru">Рак паренхимы почки. Клинические рекомендации Минздрава России. Доступно по: https://cr.minzdrav.gov.ru/view-cr/10_4</mixed-citation></citation-alternatives></ref><ref id="B15"><label>15.</label><mixed-citation>Gershman B., Moreira D.M., Thompson R.H. et al. Renal cell carcinoma with isolated lymph node involvement: long-term natural history and predictors of oncologic outcomes following surgical resection. Eur Urol 2017;72(2):300–6. DOI: 10.1016/j.eururo.2016.12.027</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Lenis A.T., Donin N.M., Johnson D.C. et al. Adjuvant therapy for high risk localized kidney cancer: emerging evidence and future clinical trials. J Urol 2018;199(1):43–52. DOI: 10.1016/j.juro.2017.04.092</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Choueiri T.K., Tomczak P., Park S.H. et al. KEYNOTE-564 Investigators. Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma. N Engl J Med 2021;385(8):683–94. DOI: 10.1056/NEJMoa2106391</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Powles T., Tomczak P., Park S.H. et al. KEYNOTE-564 Investigators. Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2022;23(9):1133–44. DOI: 10.1016/S1470-2045(22)00487-9 Erratum in: Lancet Oncol 2023;24(1):e10. DOI: 10.1016/S1470-2045(22)00759-8</mixed-citation></ref></ref-list></back></article>
